clonoSEQ (MM, BM)
Multiple Myeloma
FDA-ClearedCommercial
Key Facts
About Adaptive Biotechnologies
Adaptive Biotechnologies is a commercial-stage company on a mission to harness the adaptive immune system as a natural diagnostic and therapeutic tool. Its core achievement is the development of the Immune Medicine Platform, which sequences and maps immune receptors at scale, enabling both its growing clonoSEQ MRD diagnostics business and a deep drug discovery pipeline. The company's strategy is to leverage its unique, data-generating platform to create a sustainable competitive moat across both diagnostics and therapeutics, aiming to transform the detection, monitoring, and treatment of disease.
View full company profileOther Multiple Myeloma Drugs
| Drug | Company | Phase |
|---|---|---|
| PRG1801 (Anti-BCMA CAR-T) | Pregene Biopharma | Phase 1 |
| CAR-NK Therapy | Pregene Biopharma | Phase 1 |
| Tasquinimod | Active Biotech | Preclinical |
| BCMA CAR-T | Simnova Biotherapeutics | Phase 1 |
| BCMA panCAR (via Orna partnership) | Simnova Biotherapeutics | Preclinical |
| Measovir®-based candidate | Oncovita | Pre-clinical |
| Kyprolis® (carfilzomib) | Cleo Life Sciences | Approved |
| inobrodib (CCS1477) | CellCentric | Phase 1/2 |
| ISB 2001 | Ichnos Glenmark Innovation | Phase 1b |
| In Vivo Cell Therapy | GigaMune | Pre-clinical |
| Hemady | Dexcel Pharma USA | Approved |
| AV-353 | AVEO Oncology | Pre-clinical |